Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 65
Filter
7.
Jpn J Cancer Res ; 91(8): 774-9, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10965016

ABSTRACT

Helicobacter pylori is thought to be involved in the pathogenesis of gastric cancer, but the time point at which it produces its effects (critical time) is unknown. We measured the serum level of H. pylori antibody in 787 gastric cancer patients and 1007 controls aged 20 to 69. Odds ratios for different gastric cancer types and stages were determined for each 10-year age class. The overall odds ratio for gastric cancer decreased with age, being 7.0 for those aged 20 - 29, 14.5 for those aged 30 - 39, 9.1 for those aged 40 - 49, 3.5 for those aged 50 - 59, and 1.5 for those aged 60 - 69 (trend in odds ratios: P < 0.01). However, there was no such age-dependent trend for early diffuse-type cancer; the odds ratios were 12.6, 4.0, 7.2, 6.5, and 18.5 respectively (P = 0.29). Early cancer tended to show higher seroprevalence than advanced cancer, especially in older subjects. No significant difference in seroprevalence was observed between diffuse and intestinal cancers within each age-class. Seroreversion must have occurred in the time interval between the critical time and the diagnosis of the cancer, especially in older patients. The age-dependent relationship between H. pylori and gastric cancer may be due to seroreversion, which itself may be independent of age. This age-independence indicates that prolonged exposure to H. pylori does not increase the magnitude of its influence on gastric carcinogenesis. Possible mechanisms through which H. pylori exerts pathogenic effects are continuous inflammation in adulthood and / or irreversible damage to gastric mucosa in childhood or the teenage years.


Subject(s)
Aging , Helicobacter Infections/complications , Helicobacter pylori , Stomach Neoplasms/microbiology , Adult , Age Factors , Aged , Aging/immunology , Female , Helicobacter Infections/epidemiology , Helicobacter Infections/immunology , Helicobacter pylori/immunology , Humans , Male , Middle Aged , Odds Ratio , Risk Factors , Seroepidemiologic Studies , Stomach Neoplasms/epidemiology , Stomach Neoplasms/immunology
12.
Cancer ; 86(9): 1638-48, 1999 Nov 01.
Article in English | MEDLINE | ID: mdl-10547535

ABSTRACT

BACKGROUND: Accurate preoperative staging is an important but difficult problem in determining therapy for patients with esophageal carcinoma. Positron emission tomography (PET) is used with [methyl-(11)C]choline ((11)C-choline) and 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) to detect a variety of malignancies. The authors used PET with both of these agents to detect lymph node metastases in patients with esophageal carcinoma. METHODS: Lymph node metastases in 33 patients with biopsy-proven esophageal carcinoma (16 patients with tumors classified as T1 and 17 patients with tumors classified as T2-4) was examined by PET using (11)C-choline and (18)F-FDG, and the accuracy of the results was correlated with pathology findings after surgery. RESULTS: (11)C-choline PET was more effective than (18)F-FDG PET and computed tomography (CT) in detecting very small metastases localized in the mediastinum. It was ineffective, however, in detecting metastases localized in the upper abdomen, because of the normal uptake of (11)C-choline in the liver. (18)F-FDG PET was superior to CT in detecting metastases in the mediastinum and the upper abdomen, whereas (11)C-choline PET was superior to (18)F-FDG PET in detecting metastases in the mediastinum. When (11)C-choline PET and (18)F-FDG PET were used in combination, they were very effective in evaluating the lymph node status in both the mediastinum and the upper abdomen, and detected 85% of the metastatic lymph nodes (n = 46). CONCLUSIONS: In this study, the combination of (11)C-choline PET and (18)F-FDG PET was very effective in evaluating the lymph node status of patients with esophageal carcinoma preoperatively.


Subject(s)
Carbon Radioisotopes , Choline , Esophageal Neoplasms/diagnostic imaging , Fluorodeoxyglucose F18 , Lymph Nodes/diagnostic imaging , Neoplasm Staging/methods , Tomography, Emission-Computed/methods , Aged , Aged, 80 and over , Esophageal Neoplasms/pathology , Female , Humans , Lymph Nodes/pathology , Male , Middle Aged , Sensitivity and Specificity , Time Factors
14.
Gan To Kagaku Ryoho ; 25(4): 516-21, 1998 Mar.
Article in Japanese | MEDLINE | ID: mdl-9530357

ABSTRACT

Our experience of treatment of gastric cancer in European and developing countries suggested the necessity of the establishment of both operative and chemotherapeutic modalities. These modalities should be first based on theoretically convincing data and secondarily well analyzed from the viewpoint of cost-effectiveness.


Subject(s)
International Cooperation , Stomach Neoplasms/therapy , Cost-Benefit Analysis , Developing Countries , Europe , Humans , Lymph Node Excision , Lymphatic Metastasis , Stomach Neoplasms/economics , Stomach Neoplasms/pathology
15.
Jpn J Clin Oncol ; 27(4): 248-50, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9379513

ABSTRACT

The treatment of patients with thoracic esophageal cancer invading adjacent organs is controversial. The effect, on survival, of esophagectomy with regional node dissection after combined chemotherapy and radiotherapy was studied in six patients with the esophageal cancer. Two patients undergoing esophagectomy survived > 39 months without relapse. Postoperative complications were not observed in patients undergoing esophagectomy with a two-step surgical procedure (interval of several weeks between esophagectomy and reconstruction), while complications were observed in all patients undergoing a one-stage surgical procedure. Two-step esophagectomy with regional node dissection after combined chemo- and radiotherapy is a promising option for patients with esophageal cancer invading adjacent organs.


Subject(s)
Esophageal Neoplasms/surgery , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Aorta/pathology , Cisplatin/administration & dosage , Combined Modality Therapy , Disease Progression , Disease-Free Survival , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/pathology , Esophageal Neoplasms/radiotherapy , Esophagectomy/adverse effects , Esophagectomy/methods , Humans , Lymph Node Excision , Middle Aged , Neoplasm Invasiveness , Postoperative Complications , Pulmonary Veins/pathology , Radiotherapy Dosage , Remission Induction , Survival Rate , Thorax , Trachea/pathology , Vena Cava, Superior/pathology , Vindesine/administration & dosage
17.
Nihon Kyobu Shikkan Gakkai Zasshi ; 35(5): 583-7, 1997 May.
Article in Japanese | MEDLINE | ID: mdl-9234640

ABSTRACT

A 59-year-old woman was admitted to the hospital with a one-month history of hemoptysis, generalized fatigue, and a high fever. A chest X-ray film obtained on admission showed a massive right-sided pleural effusion. Examination of an aspirate showed a high level of amylase, and bacteria that were the same as oral bacteria. Closed drainage yielded ichorous pus and food residues, which led us to the diagnosis of empyema caused by esophageal perforation. Esophagography and fiberoptic esophagoscopy revealed that an esophagobronchial fistula related to an advanced esophageal carcinoma had caused the empyema. Surgical resection was done, and the patient was alive at the time of this writing, 7 months after she was first treated. Esophageal carcinoma is sometimes accompanied by esophagobronchial fistula. Patients with this condition usually have severe respiratory symptoms; those presenting with empyema are rare. Esophageal carcinoma must be carefully ruled out as the cause of empyema.


Subject(s)
Bronchial Fistula/etiology , Carcinoma, Squamous Cell/complications , Empyema/etiology , Esophageal Fistula/etiology , Esophageal Neoplasms/complications , Female , Humans , Middle Aged
18.
Semin Oncol ; 24(2 Suppl 6): S6-1-6, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9151909

ABSTRACT

The surgical results and postoperative management of 90 patients with hepatocellular carcinoma (HCC) who underwent hepatectomy were reviewed, and clinical factors relating to HCC were analyzed to determine what type of HCC responds best to hepatectomy. The patients consisted of 69 men and 21 women. Serum anti-hepatitis C virus was positive in 76.9% of patients and hepatitis B surface antigen was positive in 18.9%. The operative procedures consisted of right lobectomy in six patients, left lobectomy in seven, right hepatic segmentectomy in eight, left lateral segmentectomy in 13, two adjoining subsegmentectomy in 17, subsegmentectomy in 29, and partial hepatectomy in 10. Liver cirrhosis was confirmed histopathologically in 63 patients. There were two operative deaths and two other in-hospital deaths. During the follow-up period, HCC recurred in 64 of the remaining 86 patients at the following sites: liver in 56 patients (87.5%), bones in four (6.3%), lymph nodes in three (4.7%), and lung in one (1.6%). Transcatheter arterial chemoembolization was performed in 22 of the patients with recurrence, transcatheter arterial chemoembolization in combination with percutaneous ethanol injection was performed in 14, hepatectomy was performed in six, and irradiation with Linac x-rays was performed in eight. The cumulative 3- and 5-year survival rates were 63.8% and 37.8%, respectively. Univariate and multivariate analyses of factors influencing survival disclosed that having a single HCC nodule of up to a maximal diameter of 4.0 cm, an absence of intrahepatic metastasis, and a functional liver reserve estimated as clinical stage I contributed significantly and independently to increasing the survival rate.


Subject(s)
Carcinoma, Hepatocellular/surgery , Hepatectomy , Liver Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Female , Follow-Up Studies , Hepatectomy/methods , Humans , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Male , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local , Survival Rate
19.
Int J Pancreatol ; 20(3): 191-6, 1996 Dec.
Article in English | MEDLINE | ID: mdl-9013280

ABSTRACT

CONCLUSION: Pancreatic exocrine hypofunction is markedly deteriorated during acute exacerbation in a rat model with chronic pancreatitis. BACKGROUND: Little is known about pancreatic exocrine function during acute exacerbation in patients with chronic pancreatitis. We investigated changes in pancreatic exocrine function after inducing acute pancreatitis in an animal model of spontaneous chronic pancreatitis. METHODS: WBN/Kob rats with chronic pancreatitis sequentially underwent pancreatic exocrine function test 1-6 d after surgical preparation with external pancreatic fistula. We induced acute pancreatitis in another WBN/Kob rats by i.v. administration of cerulein at a rate of 10 micrograms/kg/h for 4 h 4 d after surgical preparation. Pancreatic exocrine function test was undertaken in a conscious state 1 d before and after cerulein administration. RESULTS: In WBN/Kob rats not given cerulein, pancreatic exocrine function remained almost constant at 3-6 d after surgery. Marked hyperamylasemia developed immediately after cerulein administration. After its administration, the pancreas microscopically showed prominent interstitial edema and intracellular vacuolization of acinar cells in addition to the finding of pre-existing chronic pancreatitis. Basal and cholecystokinin-stimulated flow rate, bicarbonate output, and protein output, which were substantially impaired 1 d before cerulein administration, were further reduced 1 d after its administration.


Subject(s)
Pancreas/physiopathology , Pancreatitis/physiopathology , Acute Disease , Amylases/blood , Animals , Ceruletide , Chronic Disease , Disease Models, Animal , Dose-Response Relationship, Drug , Male , Pancreatic Function Tests , Pancreatic Juice/chemistry , Pancreatic Juice/drug effects , Pancreatitis/chemically induced , Pancreatitis/pathology , Rats , Rats, Inbred Strains , Sincalide/pharmacology
20.
Strahlenther Onkol ; 172(9): 496-500, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8830812

ABSTRACT

BACKGROUND/AIM: Several reports have demonstrated that occasional long-term survival might be obtained with external beam radiation therapy in patients with gallbladder cancer. However, there are few reports which evaluate the local effect of irradiation. The aim of our study was to investigate the local effect of radiation therapy. and to evaluate its role for locally advanced gallbladder cancer. PATIENTS AND METHODS: Twenty-two patients with locally advanced gallbladder cancer were treated with high-dose external beam radiation therapy. Tumor resection was performed in 5 patients, palliative surgery in 5, and the remaining 12 patients were treated by radiation therapy alone. RESULTS: Overall survival was 36% at 1 year, 18% at 3 years and 14% at 5 years. All but 2 patients developed local recurrence and died of disease at 1 to 99 months after radiation therapy. Among 17 patients who had not undergone tumor resection, partial response was obtained in 4 patients and no response in 13. Survival times in patients who achieved partial response were 14, 26, 47 and 99 months, whereas those of no response were 1 to 12 months with a mean of 4.8 months. Survival between these 2 groups (partial vs. no response) showed significant difference (p = 0.0008, logrank test). CONCLUSION: It is concluded that high-dose external beam radiation therapy could improve survival in some patients with unresectable gallbladder cancer.


Subject(s)
Adenocarcinoma/radiotherapy , Gallbladder Neoplasms/radiotherapy , Adenocarcinoma/mortality , Adenocarcinoma/surgery , Aged , Aged, 80 and over , Female , Follow-Up Studies , Gallbladder Neoplasms/mortality , Gallbladder Neoplasms/surgery , Humans , Karnofsky Performance Status , Male , Middle Aged , Palliative Care , Radiotherapy Dosage , Survival Rate , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...